WESTON, Fla., July 8, 2004 (PRIMEZONE) -- TheSUBWAY.com announces the following stocks to its Stock Focus List: L.A.M. Pharmaceutical (OTCBB:LAMP), Corvis Corporation (Nasdaq:CORV), Siebel Systems Inc. (Nasdaq:SEBL), Celerity Systems Inc. (OTCBB:CESY).
LAM Pharmaceutical, Corp. (OTCBB:LAMP) just announced that a successful LAM IPM Wound Gel(TM) pre-launch conference took place in Panama City on June 26th and June 27th. LAM is pleased to announce it has received its first order from the region in excess of $10,000 immediately following the conference, which will be recorded in the Company's third quarter results.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and business offices in Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases.
Other stocks highlighted include Corvis Corporation (Nasdaq:CORV): Stock Focus List, Siebel Systems Inc. (Nasdaq:SEBL): Stock Focus List, Celerity Systems Inc. (OTCBB:CESY): Stock Focus List.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed.
ABOUT TheSUBWAY.com:
TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com/sub_comm.asp.
All material herein was prepared by Capital Research Group, Inc. ("CRG") based upon information supplied by L.A.M. Pharmaceutical Corp. (OTCBB:LAMP) or other sources believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. LAMP has not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com. LAM Pharmaceutical Corp. -- CRG received from LAMP three million fifty nine thousand three hundred sixty three (3,059,363) shares of common stock of LAMP, one hundred ninety thousand dollars (crg could receive up to one hundred forty thousand additional dollars) and two warrants, one of which entitles CRG to purchase, at any time and from time to time through March 24, 2004, one million shares of LAMP common stock at a purchase price of $0.22 per share and the other of which entitles CRG to purchase that number of shares, if any, of LAMP common stock equal to ten percent (10%) of the total number of shares of LAMP common stock issued or committed to be issued (including shares underlying any securities which are convertible into shares of LAMP common stock but excluding any shares included in the Selling Shareholder table of LAMP'S prospectus dated November 25, 2003 (see www.sec.gov) by LAMP during the ninety (90) day period commencing November 25, 2003. This warrant may be exercised at a price of $0.01 per share at any time but prior to the later to occur of (i) March 24, 2004; or (ii) 30 days after LAMP notifies CRG in writing of the issuance by LAMP of shares which are issuable upon the exercise of this warrant. CRG intends to sell its shares. From November 26 through Janyary 31, 2004, CRG sold approximately three million of such LAMP shares. CRG may sell its shares for less than any target price given in this opinion. CRG's affiliates, officers, directors and employees may also have bought or may buy shares (pursuant to the exercise of warrants or otherwise) discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.